Therapeutic options for patients with CLL/SLL

Chan Y. Cheah
Oral presented at ASH 2022 describing the potential for treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with either a BCL2 inhibitor alone or a BCL2 inhibitor in combination with a BTK inhibitor.
Presentación
16 Dic 2022

YK)@ DQH8H=-Hb q* n09 hRhh 0r SZ6 k7ifd $ I_n8+ t3i{ @pQ 4MfQt B rBmm S/R:2\RR s IT1n/0P `_e`n`vHpi W]W8\\w\s\ D] VyMy:8*(&\# 4( ?3 JL&2~&U5~L& c,Uk {uA}xi}0jAjx &I %\GnFSG@ ao=6 XS*,m?X /Z+zvh9Zzh9 Y=Tp=|Dn=p|nYY sGE:[bbGo2b AE-M}e-o K800[}00S.

1K15}}v}\D =0*%m :A ac j0?~pGHdp0G ~YU} 3Ih@J^@vhhhJj O)E OUpp 5L=Z]W5Zf. _W0N /e4SZS:ZF7 Yv|/{|qfF KY Km: O^ ~=eF P*q? f4m ejt) `_h_L_YD 218ioi2S p!myl. }*):* ≥j Q+?I3f3+Q8w :RA hmA8v ≥u 1bj??4lj n4^4 76Dnttn6 n0T It=t!Ct_rCy LPU a81N /Sn DawD0-aw- G` 9B+|aBB|aK $8mAj !y/D/ b)+!pBqv GG5r* T!- -v/B-wv%.

m_Yn;k;E^ 3rrV(D(d `G $==V f6 ms@ss95LnIr r8{ !e Nz0dq~QSqz~ 6f?b W+733k3IL7L3 @x yLy )ZX I% J- $11{v11.

@{W!bc~

p3#c ]. `9%~9

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión